Correction: The Role of Neutrophil Extracellular Traps in Interactions with Macrophages and Their Implications for Inflammatory Disorders - Scorecard - MDSpire

Correction: The Role of Neutrophil Extracellular Traps in Interactions with Macrophages and Their Implications for Inflammatory Disorders

  • By

  • Xiaoyu Shan

  • Xiaodong Fan

  • Xiaofei Geng

  • Yongchun Liang

  • Yingxi Yang

  • Junping Zhang

  • April 24, 2026

  • 0 min

Share

Clinical Scorecard: Correction: The Role of Neutrophil Extracellular Traps in Interactions with Macrophages and Their Implications for Inflammatory Disorders

At a Glance

CategoryDetail
ConditionInflammatory Disorders
Key MechanismsInteractions between neutrophil extracellular traps and macrophages
Target PopulationIndividuals with inflammatory disorders
Care SettingClinical and research settings

Key Highlights

  • Correction of author affiliations and order
  • Updated author contributions statement
  • Identification of corresponding authors

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Not specified in the correction

          Not specified in the correction

          Clinical Best Practices

          • Ensure accurate author affiliations
          • Maintain correct author order
          • Clearly identify corresponding authors

          References

          Original Source(s)

          Correction: The Role of Neutrophil Extracellular Traps in Interactions with Macrophages and Their Implications for Inflammatory Disorders

          • by Xiaoyu Shan, Xiaodong Fan, Xiaofei Geng, Yongchun Liang, Yingxi Yang, Junping Zhang

          • April 24, 2026

          Related Content

          Upadacitinib and Pain in RA, PsA

          Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

          Mandatory Training Modules Deserve a Harder Look

          A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

          FDA Clears Self-Administered Lupus Therapy

          Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.